Your browser doesn't support javascript.
loading
Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event.
Terasaki, K; Ueno, A; Mizuno, C; Shima, T; Okanoue, T.
Affiliation
  • Terasaki K; Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
  • Ueno A; Department of Urology, Saiseikai Suita Hospital, Osaka, Japan.
  • Mizuno C; Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
  • Shima T; Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
  • Okanoue T; Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
J Gastroenterol Hepatol ; 37(8): 1472, 2022 08.
Article in En | MEDLINE | ID: mdl-35141946
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Ulcer / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: J Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2022 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Ulcer / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: J Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2022 Document type: Article Affiliation country: Japan